Sign Out
Hypersensitivity to levodopa, carbidopa or any ingredient of the product.
Concomitant use with nonselective monoamine oxidase inhibitors (MAOIs). These inhibitors must be discontinued at least two weeks prior to initiating therapy with levodopa + carbidopa. Levodopa + carbidopa may be administered concomitantly with the manufacturer's recommended dose of a MAO inhibitor with selectivity for MAO type B (e.g., selegiline hydrochloride).
Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hematologic, hepatic, pulmonary (including bronchial asthma), or renal disease.
Narrow angle glaucoma.
When administration of a sympathomimetic amine is contraindicated (e.g., epinephrine, norepinephrine or isoproterenol).
Severe psychoses.
Suspicious undiagnosed skin lesions or a history of melanoma since levodopa may activate a malignant melanoma.
Continue with Google